107.20
8.80 (8.94%)
前收盘价格 | 98.40 |
成交量 | 174,070 |
平均成交量 (3个月) | 3,910,633 |
市值 | 1,024,239,104 |
价格/销量 (P/S) | 8.87 |
股市价格/股市净资产 (P/B) | 2.97 |
52周波幅 | |
利润日期 | 4 Mar 2025 |
营业毛利率 | -79.80% |
营业利益率 (TTM) | -75.99% |
稀释每股收益 (EPS TTM) | -0.160 |
季度收入增长率 (YOY) | 18.50% |
总债务/股东权益 (D/E MRQ) | 7.84% |
流动比率 (MRQ) | 4.66 |
营业现金流 (OCF TTM) | -109.89 M |
杠杆自由现金流 (LFCF TTM) | -82.20 M |
资产报酬率 (ROA TTM) | -12.53% |
股东权益报酬率 (ROE TTM) | -23.77% |
市场趋势
短期 | 中期 | ||
行业 | Biotechnology (GB) | 混合的 | 混合的 |
Biotechnology (全球的) | 混合的 | 看跌 | |
股票 | OXFORD NANOPORE TECHNOLOGIES PL | - | - |
AIStockmoo 评分
分析师共识 | 0.0 |
内部交易活动 | NA |
价格波动 | 0.5 |
技术平均移动指标 | -2.5 |
技术振荡指标 | -0.5 |
平均 | -0.63 |
相关股票
股票 | 市值 | DY | P/E(TTM) | P/B |
---|---|---|---|---|
OXFORD NANOPORE TECHNOLOGIES PL | 1 B | - | - | 2.97 |
ARROWHEAD PHARMACEUTICALS INC A | 2 B | - | - | - |
RELIEF THERAPEUTICS HOLDING SA | 2 B | - | - | - |
IDORSIA LTD IDORSIA N ORD SHS | 1 B | - | - | - |
BASILEA PHARMACEUTICA AG BASILE | 560 M | - | - | - |
IOVANCE BIOTHERAPEUTICS INC IOV | 401 M | - | - | - |
Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The company is predominantly involved in researching, developing, manufacturing, and commercializing a nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company's reportable segments are; Life Science Research Tools which generates key revenue, and COVID Testing. |
|
部门 | Healthcare |
行业 | Biotechnology |
投资方式 | Small Value |
内部持股比例 | 42.94% |
机构持股比例 | 43.11% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合